– CANADA, Mississauga – NOVADAQ Technologies Inc. (NASDAQ:NVDQ) (TSX:NDQ), the leading developer and provider of clinically relevant imaging solutions for use in surgical and diagnostic procedures, announced today the appointment of Rick Mangat, Ph.D. as its President and CEO.
Dr. Mangat succeeds Arun Menawat, who has resigned as the Company’s President, CEO and Chair of its Board of Directors, to pursue new opportunities and interests. Additionally, Bill MacKinnon, former CEO of KPMG Canada and head of the NOVADAQ audit committee, has been appointed Chairman of the Board.
Dr. Mangat is a co-founder of NOVADAQ and co-inventor of the Company’s SPY imaging technology. Since 2014, he has served as NOVADAQ’s Sr. Vice-President and General Manager, overseeing development of the company’s global sales and marketing team. “I look forward to the opportunity to build on NOVADAQ’s strong foundation,” said Dr. Mangat. “We are well-positioned to fully leverage a new clinical ecosystem that provides relevant imaging solutions for use in multiple patient care applications.”
As CEO, Dr. Mangat succeeds Dr. Menawat, who has served as NOVADAQ’s President and CEO since 2003. During his tenure, Dr. Menawat successfully guided the Company’s successful progression from a start-up to an international market leader in the field of fluorescence imaging.
“It has been an honor and privilege to have worked alongside the talented and dedicated team at NOVADAQ for the past thirteen years,” said Dr. Menawat. “I am leaving it in good hands, poised to build upon its position as a market leader in a rapidly growing field.”
“On behalf of the Board, management and staff of NOVADAQ, I would like to take this opportunity to thank Arun for his many contributions to the Company’s success,” said Anthony Griffths, Lead Director of NOVADAQ’s Board. “He has earned our respect and admiration, and he will be missed. At the same time, I am very pleased that Rick has agreed to accept this leadership role at such an exciting time in NOVADAQ’s journey.”
About Novadaq Technologies Inc.
Enabling medical professionals with clinically relevant, point-of-care imaging solutions to enhance the lives of patients and their caregivers, while reducing health care costs, is NOVADAQ’s global mission. SPY fluorescence imaging technology provides surgeons with real-time visualization, leading to improved outcomes and reduced costs without exposing the patient to radiation. More than 180 peer-reviewed publications demonstrate that the use of SPY imaging technologies during complex surgery and diagnostic procedures, leads to lower rates of post-operative complications and lower hospital costs.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
